One of Novartis' would-be blockbusters generated promising late-stage data as a therapy for chronic obstructive pulmonary disease. Compared with a standard treatment option for COPD, QAB149 demonstrated improved lung function at 12 weeks and 26 w...

Savient Pharmaceuticals announced on Sunday that the FDA issued a complete response letter for the drugmaker's gout drug Krystexxa (pegloticase), causing the company's shares to fall 38 percent in premarket trading on Monday. K...

Vaccine developer Novavax announced a new deal with Spain's health ministry and drugmaker ROVI Pharmaceuticals Tuesday afternoon, sending its stock soaring 35 percent in afternoon trading. Spanish officials have committed €60 ...

Shares of Osiris Therapeutics slid nearly 10 percent in after-hours trading after the developer announced that interim data on Prochymal--a cutting-edge adult stem cell therapy--failed to demonstrate an improvement in pulmonary function in COPD...

Shares of Spain's Zeltia wilted after U.S. regulators raised serious questions regarding its flagship cancer drug Yondelis.